WB-F344大鼠肝上皮样干细
- 公司名称 上海富雨生物科技有限公司
- 品牌 富雨生物
- 型号
- 产地
- 厂商性质 生产厂家
- 更新时间 2025/2/12 16:01:12
- 访问次数 106
联系方式：陈寿彬18956075901 查看联系方式
联系我们时请说明是化工仪器网上看到的信息，谢谢!
大鼠肝上皮样干细胞WB-F344
| 种属 | 大鼠 |
| 别称 | WB F344; WBF344 |
| 组织来源 | 肝脏 |
| 疾病 | 自发永生化细胞 |
| 传代比例/细胞消化 | 1:2传代,消化1-2分钟 |
| 培养基配置 | DMEM养基；10%胎牛血清；1%双抗 |
| 形态 | 上皮细胞样 |
| 生长特征 | 贴壁生长 |
| 倍增时间 | 每周 2 至 3 次 |
| 培养条件 | 气相：空气，95%；二氧化碳，5%。 温度：37摄氏度，培养箱湿度为70%-80%。 |
| 冻存条件 | 冻存液 ：90%FBS ，DMSO 10%, 或使用非程序冻存液 ：货号JY-H040 |
| 保藏机构 | JCRB; JCRB0193 |
| 产品使用 | 于科学研究 ，不可作为动物或人类疾病的治疗产品使用。 |
Results: The cohort had a mean age of 39 years and included patients with severe polytrauma. Technical success was achieved in 95% of cases, with no intraoperative deaths or need for open surgical conversion. Perioperative complications were minimal, and the reintervention rate was 5.3%. This study evaluates 10 years of clinical experience managing TAI with TEVAR. Long-term follow-up, with a median duration of 29 months, revealed no graft-related complications or secondary interventions. Imaging confirmed sustained graft integrity, and clinical outcomes were favorable.
Conclusion: TEVAR is a reliable and effective treatment for traumatic aortic injuries, offering excellent technical success rates and minimal perioperative and long-term complications. This study highlights TEVARs advantages in managing polytrauma patients and its role as a minimally invasive alternative to open surgery. Additionally, the findings emphasize the need for comprehensive long-term follow-up protocols. Future research should aim to address challenges related to device durability and the integration of advanced imaging techniques to further enhance patient outcomes and broaden the applicability of TEVAR in trauma care.
采购中心
化工仪器网